MEMaliheh Entezari

Maliheh Entezari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maliheh Entezari has a total of 379 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Natural bioactive molecules and chemotherapeutics synergism for enhanced cancer therapy

    by Mehrdad Hashemi, Katayoun Heshmatzad, Ghazaleh Shahsavan, Vahid Tavakolpour, Sara Komeilie Esfahani, Pardis Karimi, Naghmeh Beikzadeh, Saba Mashhadikhan, Sevda Nasirzade, Ali Vasheghani Farahani, et al.

    Background: Chemotherapy remains a foundation of cancer care but is limited by multidrug resistance, systemic toxicities, and suboptimal selectivity, prompting interest in adjunctive strategies that improve efficacy and tolerability without adding significant burden to patients or healthcare systems. Aims/Objectives: This review highlights evidence on natural bioactive compounds, including polyphenols, alkaloids, terpenoids, and fungal metabolites, as adjuvants to standard chemotherapeutics, with objectives to: first, delineate mechanisms by which these agents enhance cytotoxic efficacy and overcome resistance; second, summarize preclinical and clinical combination data; and third, evaluate their potential to mitigate chemotherapy-induced organ toxicities through pathway modulation. Results: Natural bioactives modulate key oncogenic and stress-response pathways, such as NF-κB, PI3K/AKT/mTOR, and NRF2/HO-1, thereby sensitizing tumors to chemotherapy, attenuating pro-survival signaling, and enhancing apoptosis while reducing inflammatory and oxidative injury in normal tissues. Exemplary combinations, including curcumin with 5‑fluorouracil and resveratrol with cisplatin, have demonstrated improved antitumor activity and reduced toxicity in preclinical models, with early clinical observations supporting feasibility and safety in selected settings. Additionally, several compounds exhibit organ-protective effects against cardiotoxicity, nephrotoxicity, neurotoxicity, and gastrointestinal injury induced by chemotherapy, suggesting dual benefits on efficacy and tolerability profiles. Conclusions: Integrating natural bioactives with conventional chemotherapy represents a promising strategy to enhance therapeutic index by concurrently amplifying antitumor mechanisms and mitigating dose‑limiting toxicities, though broader clinical validation and standardized quality controls are needed for routine adoption. Graphical


  • MicroRNAs and Long Non-Coding RNAs Affect the Mechanisms Involved in Age-Related Neurodegeneration in a Manner Depending on RNA-Binding Proteins

    by Mehrdad Hashemi, Pezhman Shafiei Asheghabadi, Mahdi Moassesfar, Saba Mashhadikhan, Sevda Nasirzade, Ali Vasheghani Farahani, Shaghayegh Mehdizadeh, Shinoo Minaei, Maryam Rahmani, Faranak Jamshidian, et al.

    Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD), are marked by progressive neuronal loss and aberrant protein aggregation, presenting substantial global healthcare challenges. Recent research has illuminated the pivotal roles of RNA-binding proteins (RBPs) and non-coding RNAs (ncRNAs), notably microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in the molecular pathogenesis of age-related neurodegeneration. RBPs orchestrate RNA metabolism and engage extensively with miRNAs and lncRNAs to modulate gene expression at the post-transcriptional level. Dysregulation of these interactions precipitates pathological phenomena such as protein misfolding, stress granule formation, and disrupted RNA processing, thereby exacerbating neuronal dysfunction and death. Specific miRNAs have been implicated in regulating key neurodegenerative biomarkers, including tau and amyloid-β in AD, motor neuron maintenance in ALS, and survival pathways in HD. Elucidating the intricate interplay between RBPs and ncRNAs holds significant promise for the development of therapeutic strategies aimed at ameliorating RNA-mediated mechanisms in neurodegenerative disorders. Graphical Abstract


  • Open Access

    Nutritional approaches in combating therapeutic resistance and enhancing treatment efficacy in cancer: the impact of ketogenic diets

    by Lei Wang, Pezhman Shafiei Asheghabadi, Saba Mashhadikhan, Sevda Nasirzade, Yeganeh Ettehad, Sepideh Gholamrezaie, Fatemeh Jafari, Maryam Rahmani, Shaghayegh Mehdizadeh, Neda Zali, et al.

    Cancer remains a major global health challenge, with therapeutic resistance significantly limiting treatment success. Traditional approaches, including surgery, chemotherapy, and radiotherapy, often encounter barriers such as metastasis and adverse effects on healthy tissues. The Warburg effect, which describes cancer cells’ reliance on glucose fermentation despite oxygen availability, has prompted investigations into alternative metabolic interventions. The ketogenic diet (KD), characterized by high fat intake and low carbohydrate intake, induces a metabolic shift that may selectively disadvantage malignant cells while preserving normal tissue function. While emerging evidence, including preclinical studies, early-phase trials, and limited clinical series, suggests that KD may help overcome treatment resistance by suppressing the PI3K/Akt/mTOR pathway, reducing insulin-like growth factor-1 (IGF-1) signaling, and enhancing cancer cell susceptibility to chemotherapy and targeted therapies, robust data from large, randomized controlled trials (RCTs) remain sparse. Most current findings derive primarily from animal models and small pilot studies, with definitive efficacy and safety in broad patient populations yet to be established. Preclinical and preliminary clinical studies indicate KD’s potential in modulating epigenetic markers, reducing inflammation, and improving patient metabolic health. However, patient adherence remains challenging and standardized protocols are still under development. This review explores the molecular mechanisms underlying KD’s anticancer effects, its role in mitigating drug resistance, and current translational insights, with emphasis on the nascent stage of high-quality clinical trial evidence and areas for future research.


  • Open Access

    The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies

    by Mehrdad Hashemi, Niloufar Salimian, Nafiseh Sharifi, Pezhman Shafiei Asheghabadi, Zahra Zarearandi, Fatemeh Abdi, Saranaz SeyedAli Akbar, Reza Mohajer Shirazi, Mehrdad Bagheri Pozve, Armin Nikdehqan, et al.

    Hematological malignancies, including leukemia, lymphoma, and multiple myeloma (MM), are cancers originating in the hematopoietic system, characterized by diverse pathogenesis and clinical features. Non-coding RNAs (ncRNAs) such as microRNAs (miRNAs) and long non-coding RNAs, play critical roles in regulating gene expression and influencing cell fate. Accumulating evidence indicates that ncRNAs are key modulators of programmed cell death (PCD) pathways, affecting tumor development, progression, and drug resistance in these malignancies. PCD, a precisely programmed and regulated cell death process, is vital for maintaining tissue homeostasis and preventing the proliferation of dangerous cells. NcRNAs are implicated in the primary mechanisms underlying the development of drug resistance. The evasion of PCD is a hallmark of cancer, and ncRNAs can significantly impact these pathways, with dysregulation observed across leukemia, lymphoma, and myeloma, influencing PCD pathways and clinical outcomes. Understanding the ncRNA-PCD interplay is crucial for developing novel therapeutic strategies and improving patient outcomes. This review explores the functions, regulatory mechanisms, and potential applications of ncRNAs in modulating PCD in hematological malignancies, particularly leukemias, providing insights for future anti-tumor therapies. • Leukemias, lymphomas, and myelomas are primary types of hematological neoplasms. • It has been revealed that programmed cell death (PCD) impacts cancer progression. • NcRNAs in this regard are critical in modulating cell death pathways. • Targeting ncRNAs and PCD may enhance hematological malignancies treatments.

  • Exploiting autophagy and related pathways: pioneering new horizons in cataract therapy

    by Mehrdad Hashemi, Pezhman Shafiei Asheghabadi, Mahdi Moassesfar, Roya Malek Mohammadi, Nazanin Rafedoust, Maedeh Razeh, Yeganeh Esfahaniolasl, Mahsa Mirzayi, Sahar Keikhavani, Katrin Tajbakhsh, et al.

    Autophagy is a critical catabolic pathway that facilitates the degradation of intracellular components through lysosomal activity, originally recognized for its role in nutrient recycling during starvation. Recent research has expanded our understanding of autophagy, revealing its involvement in various physiological processes essential for cellular, tissue, and organismal homeostasis. Dysregulation of autophagy has been linked to numerous diseases, including ocular conditions such as cataracts. In human lens fibers, autophagic vesicles containing mitochondria or mitochondrial fragments have been identified, underscoring the importance of autophagy in maintaining lens integrity and transparency. Disruptions in organelle elimination can lead to increased reactive oxygen species (ROS), altering lens homeostasis and contributing to cataract formation. Recent studies have highlighted the complex interplay between autophagy and lens epithelial cells (LECs) in both age-related and diabetic cataract development. In age-related cataracts, increased autophagic activity coincides with elevated apoptosis in LECs, suggesting a bidirectional regulatory role of autophagy in cellular senescence. Additionally, the degradation of SQSTM1/p62 during oxidative stress implicates autophagy in the apoptotic processes associated with senile cataracts. In diabetic cataracts, high glucose levels disrupt the relationship between autophagy and epithelial-mesenchymal transition (EMT) in LECs via the Notch signaling pathway, leading to impaired autophagic function and subsequent cataractogenesis. These findings indicate that autophagy dysregulation is a significant contributor to the pathophysiology of various cataract types. Future research should focus on exploring the therapeutic potential of modulating autophagy to prevent or treat cataracts, investigating specific signaling pathways involved, and identifying biomarkers for early detection. By elucidating the molecular mechanisms underlying autophagy’s role in cataract formation, novel targeted therapies may emerge, providing hope for improved management and prevention of this prevalent ocular pathology. Graphical abstract


  • Open Access

    SIRT1 as a masterful reciprocal regulator of molecular mechanisms and signaling pathways involved in tumor growth and expansion

    by Mehrdad Hashemi, Neda Zali, Seyedeh Zahra Ghafarzadeh Dastjerdi, Bita Pakshad, Melika Aliahmadi, Nafiseh Sharifi, Kimia Sadat Esfahani, Fatemeh Sadat Kohandani, Sogand Chamanian, Fariba Abbasi, et al.

    Sirtuin 1, which is more commonly identified as SIRT1, is a well-recognized NAD+-dependent histone and/or protein deacetylase that operates a wide range of cellular and molecular mechanisms involved in carcinogenic processes. SIRT1 not only regulates the primary mechanisms involved in tumorigenesis but also is responsible for controlling other processes, such as cell migration and metastasis, autophagy, and apoptotic flux, as well as chemotherapeutic resistance. It is well established that SIRT1 works at the upstream of signal transduction pathways, such as p53 signaling, together with FOXO mechanism, as well as the others. Indeed, SIRT1 by its deacetylase activity deacetylates different molecules in those signaling pathways and mostly causes a kind of blockade in the signaling of interest. Nonetheless, many aspects of SIRT1–cancer relationship are ambiguous, and more experiments should be performed for further uncovering of the concept. In the current review, we first highlight the major regulators of SIRT1 in cancer and then underscore key signal transduction pathways regulated by SIRT1. In the following, the role of SIRT1 will be discussed in tumor progression, from tumorigenesis to chemotherapeutic resistance, and at last, the contribution of SIRT1 to human cancers will be exemplified by some studies conducted in the field. Graphical abstract


  • Open Access

    Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications

    by Mehrdad Hashemi, Asal Abolghasemi Fard, Bita Pakshad, Pezhman Shafiei Asheghabadi, Amineh Hosseinkhani, Atena Sadat Hosseini, Parham Moradi, Mohammadreza Mohammadbeygi Niye, Ghazal Najafi, Mohadeseh Farahzadi, et al.

    Lung cancer (LC) is one of the most common causes of cancer-related death worldwide. It has been demonstrated that the prognosis of current drug treatments is affected by a variety of factors, including late stage, tumor recurrence, inaccessibility to appropriate treatments, and, most importantly, chemotherapy resistance. Non-coding RNAs (ncRNAs) contribute to tumor development, with some acting as tumor suppressors and others as oncogenes. The phosphoinositide 3-kinase (PI3Ks)/AKT serine/threonine kinase pathway is one of the most important common targets of ncRNAs in cancer, which is widely applied to modulate the cell cycle and a variety of biological processes, including cell growth, mobility survival, metabolic activity, and protein production. Discovering the biology of ncRNA-PI3K/AKT signaling may lead to advances in cancer diagnosis and treatment. As a result, we investigated the expression and role of PI3K/AKT-related ncRNAs in clinical characteristics of lung cancer, as well as their functions as potential biomarkers in lung cancer diagnosis, prognosis, and treatment.


  • Translating preclinical insights into clinical strategies: Targeting cancer stem cells and stemness in prostate cancer

    by Najma Farahani, Amin Maghsoodlou, Mohammadarian Akbari, Safa Tahmasebi, Salman Daneshi, Marzieh Ramezani Farani, Ali Reza Yusefi, Payman Rahimzadeh, Afshin Taheriazam, Maliheh Entezari, et al.


  • Role of lncRNA PVT1 in the progression of urological cancers: Novel insights into signaling pathways and clinical opportunities

    by Mehrdad Hashemi, Hamidreza Gholamrezaie, Faezeh Ziyaei, Saba Asadi, Zahra Yousefian Naeini, Niloufar Salimian, Golnaz Enayat, Nafiseh Sharifi, Melika Aliahmadi, Yasamin Soofi Rezaie, et al.


  • Metastasis and chemoresistance in breast cancer: Crucial function of ZEB1/2 proteins

    by Seyed Mohammad Doodmani, Mohamad Hosein Safari, Mohammadarian Akbari, Najma Farahani, Mina Alimohammadi, Amir Reza Aref, Fatemeh Tajik, Amin Maghsoodlou, Salman Daneshi, Teimour Tabari, et al.